|
Patent landscape, scope, and claims: |
United States Patent 5,942,519: What Is Claimed and How Broad the Scope Is?
US Drug Patent 5,942,519 claims prevention or risk reduction of precipitated acute urinary retention (AUR) in male subjects by giving a 5α-reductase inhibitor, including finasteride and specific structural formula I compounds. The core novelty is not the drug class alone, but the use framing: reducing the risk of AUR that is precipitated by identifiable clinical triggers (anesthesia/surgery, specific medical events/conditions, and medication triggers).
What is the invention’s focus?
- Indication: precipitated AUR (not routine LUTS/BPH symptom relief).
- Population: male subjects at risk/susceptible to precipitated AUR.
- Intervention: 5α-reductase inhibition, delivered either as:
- finasteride, including a 5 mg/day dosing statement, and/or
- “compound(s) of structural formula I,” defined by substituent scope for R, with specific embodiments.
Claim architecture
The independent claim set is use-method oriented:
- Method for reducing risk (claims 1, 2, 9)
- Method for preventing (claims 10, 11, 18)
Then the dependent claims narrow:
- compound substituent definition (R)
- specific precipitating causes (claims 6-8, 15-17)
- specific finasteride dose (5 mg/day)
This structure matters for the landscape because it creates enforceable claim “tracks” for both:
1) finasteride at a particular dose/use context, and
2) structurally defined “formula I” compounds across a defined R-space.
Claim-by-Claim Scope: How Far Does Each Claim Reach?
Independent and semibroad claims
Claim 1
Method for reducing risk of precipitated acute urinary retention in a male subject at risk, comprising administering an effective amount of a 5α-reductase inhibitor.
Scope markers
- Broad drug-class anchor: “inhibitor of 5α-reductase”
- Broad setting: no required trigger in claim 1 (trigger specificity is added in dependent claims)
- “Risk reduction” includes prophylaxis even if AUR does not occur.
Claim 2
Like claim 1, but instead of generic class wording, it requires a compound of structural formula I, with R defined by:
- (a) C1-10 alkyl, optionally substituted with 1 to 3 halogens
- (b) phenyl, unsubstituted or substituted with up to 1 to 3 groups independently selected from:
- halogen
- methyl
- trifluoromethyl
Also includes pharmaceutically acceptable solvate or crystal form.
Scope markers
- Converts the drug-class claim into a structure-limited claim.
- Still relatively broad in R-space:
- alkyl chain up to C10 with 0–3 halogens
- phenyl ring with up to 3 allowed substituents drawn from a three-member set (halogen/methyl/CF3)
Claim 9
Method of reducing risk, comprising finasteride at 5 mg per day.
Scope markers
- Narrows to a specific active and dose.
- Enforceability leverage often comes from dose-specific use. Even if finasteride is otherwise known, a claim tied to this precise regimen for this precise prophylactic purpose is different.
Claim 10
Method for preventing precipitated AUR in a male subject susceptible thereto, comprising administering an effective amount of a 5α-reductase inhibitor.
Scope markers
- Broad again at the class level.
- “Preventing” can be interpreted as stronger than “reducing risk,” but for infringement analysis, courts often focus on whether the act falls within the claimed use.
Claim 11
Prevention method using structural formula I compounds with the same R definition as claim 2, plus solvate/crystal forms.
Claim 18
Prevention method using finasteride at 5 mg per day.
Dependent claims: narrowing levers
Claims 3-5 (compound R narrowing)
These depend from claim 2 and define R more narrowly:
- Claim 3: R is either:
- unsubstituted C1-10 alkyl, or
- phenyl unsubstituted or substituted with one or two CF3 groups
- Claim 4: R is t-butyl
- Claim 5: R is 2,5-bis(trifluoromethyl)phenyl
How this changes scope
- Claim 2 covers many halogenated alkyl and multi-substituted phenyl variants.
- Claims 3-5 create fallback positions:
- from “broad R rules” to “no halogen on alkyl” and “only CF3 substitution on phenyl” and then to two named embodiments.
Claims 6-8 (precipitating triggers for risk reduction)
-
Claim 6: the precipitating AUR is caused by one of:
- anesthesia or surgery
- precipitating medical event
- precipitating medical condition (examples given)
- ingestion of medication known to precipitate retention
-
Claim 7: narrows the event/condition/medication enumerations:
- precipitating medical event: stroke or congestive heart failure
- precipitating medical condition: prostatitis or urinary tract infection
- medication trigger: pseudoephedrine hydrochloride, cold medicine, narcotics, sedatives, benadryl
-
Claim 8: precipitating AUR is specifically anesthesia or surgery
How to read the trigger scope
- Claim 6 uses a “known to precipitate” bucket for medications and broad labels for events/conditions.
- Claim 7 locks in specific exemplars that become enforceable without having to prove the entire universe of medication triggers. It creates clean infringement pathways in common clinical scenarios.
Claims 12-14 (precipitating prevention with R narrowing)
Mirror the risk-reduction compound narrowing in claims 3-5 for prevention:
- Claim 12: unsubstituted alkyl or phenyl with 1–2 CF3
- Claim 13: t-butyl
- Claim 14: 2,5-bis(trifluoromethyl)phenyl
Claims 15-17 (precipitating triggers for prevention)
Mirror the trigger enumerations in claims 6-8:
- Claim 15: anesthesia/surgery, event, condition, medication trigger
- Claim 16: event = stroke/CHF; condition = prostatitis/UTI; med trigger = pseudoephedrine/cold medicines/narcotics/sedatives/benadryl
- Claim 17: anesthesia
What is the “Real” Scope for Product Design Around?
The patent’s scope is best understood as three overlapping claim tracks.
Track A: class-based method claims
- Claim 1 (risk reduction)
- Claim 10 (prevention)
These cover any 5α-reductase inhibitor used in the specified use context.
Design-around implication
- Pure structural substitution does not help if the product is still a 5α-reductase inhibitor and the use fits the claimed prophylaxis.
Track B: structural formula I claims
- Claims 2, 11 and their sub-variants (3-5, 12-14)
This is where chemical entities can matter:
- if a compound falls outside formula I’s structural definition (not shown in full in your excerpt), it can avoid infringement of those structural claims.
- but the class claims can still catch the use.
Design-around implication
- You can avoid structural claims only if you also avoid the class-based use claims. Otherwise, the method claims still capture functionally equivalent mechanisms.
Track C: finasteride-specific, dose-specific claims
- Claim 9 (risk reduction, 5 mg/day)
- Claim 18 (prevention, 5 mg/day)
Design-around implication
- Changing dose could avoid the literal “5 mg per day” limitation for these claims.
- The presence of broader class claims means avoiding the dose alone may not be sufficient if infringement analysis turns on whether the administered amount is still “effective” under class claims.
Trigger and Patient-Context Coverage: Where Infringement Risk Is Highest
The claims explicitly cover common precipitating contexts. This is where enforcement activity tends to concentrate because medical documentation is direct.
Common precipitating triggers enumerated
Anesthesia/surgery
- Claim 6 / 8 (risk reduction)
- Claim 15 / 17 (prevention)
Medical events
- Stroke
- Congestive heart failure
(Claim 7 for risk reduction; Claim 16 for prevention)
Medical conditions
- Prostatitis
- Urinary tract infection
(Claim 7; Claim 16)
Medication triggers
- Pseudoephedrine hydrochloride
- Cold medicine
- Narcotics
- Sedatives
- Benadryl (diphenhydramine, as labeled)
(Claim 7; Claim 16)
Clinical documentation angle
Because these are enumerated, a labeling or protocol that documents intent to prevent precipitated AUR in male subjects at risk/susceptible during such events can map cleanly to the dependent claims.
Landscape: How US 5,942,519 Likely Sits Against Competing Uses and Formulation Strategy
Positioning versus generic “BPH prophylaxis” and “5α-reductase inhibitor” prior art
Even without enumerating other patents in your prompt, the structure here indicates the novelty claim is the use for precipitated acute urinary retention risk tied to triggers and male at-risk/susceptible language, rather than general BPH symptom management.
This matters because the patent landscape for 5α-reductase inhibitors is crowded with BPH-related claims. Here, the patent tries to separate itself by:
- focusing on acute retention rather than long-term symptom scoring
- focusing on precipitating contexts rather than chronic progression.
Practical enforcement vectors
- Finasteride products: dose documentation (5 mg/day) in the prophylaxis use context.
- Other 5α-reductase inhibitors: class claims (1 and 10) capture the mechanism regardless of structure.
- Named structural exemplars: t-butyl and 2,5-bis(trifluoromethyl)phenyl R are explicitly claimed; products matching those embodiments face direct structural-claim exposure.
Scope Summary Table: What Each Claim Actually Covers
| Claim |
Method purpose |
Drug scope |
Compound scope |
Precipitating trigger scope |
| 1 |
Reduce risk |
5α-reductase inhibitor (any) |
N/A |
Not required (dependent adds) |
| 2 |
Reduce risk |
Structural formula I |
R = alkyl C1-10 with 0–3 halogens or phenyl with halogen/methyl/CF3 up to 3 substituents |
Not required (dependent adds) |
| 3 |
Reduce risk |
Structural formula I |
R = unsubstituted C1-10 alkyl or phenyl with 1–2 CF3 |
Not required (dependent adds) |
| 4 |
Reduce risk |
Structural formula I |
R = t-butyl |
Not required (dependent adds) |
| 5 |
Reduce risk |
Structural formula I |
R = 2,5-bis(CF3)phenyl |
Not required (dependent adds) |
| 6 |
Reduce risk |
From claim 1 |
N/A |
Anesthesia/surgery, medical event, condition, or known medication trigger |
| 7 |
Reduce risk |
From claim 6 |
N/A |
Event: stroke/CHF; Condition: prostatitis/UTI; Med: pseudoephedrine/cold meds/narcotics/sedatives/benadryl |
| 8 |
Reduce risk |
From claim 1 |
N/A |
Anesthesia or surgery |
| 9 |
Reduce risk |
Finasteride |
N/A |
Not required (dependent adds via claim 6) |
| 10 |
Prevent |
5α-reductase inhibitor (any) |
N/A |
Not required (dependent adds) |
| 11 |
Prevent |
Structural formula I |
Same R rules as claim 2 |
Not required (dependent adds) |
| 12 |
Prevent |
Structural formula I |
Same as claim 3 |
Not required (dependent adds) |
| 13 |
Prevent |
Structural formula I |
R = t-butyl |
Not required (dependent adds) |
| 14 |
Prevent |
Structural formula I |
R = 2,5-bis(CF3)phenyl |
Not required (dependent adds) |
| 15 |
Prevent |
From claim 10 |
N/A |
Anesthesia/surgery, medical event, condition, or known medication trigger |
| 16 |
Prevent |
From claim 15 |
N/A |
Event: stroke/CHF; Condition: prostatitis/UTI; Med: pseudoephedrine/cold meds/narcotics/sedatives/benadryl |
| 17 |
Prevent |
From claim 10 |
N/A |
Anesthesia |
| 18 |
Prevent |
Finasteride |
N/A |
Not required (dependent adds via claim 15) |
Key Takeaways
- US 5,942,519 is a use patent for precipitated acute urinary retention prevention/risk reduction in male patients using 5α-reductase inhibitors.
- The claim set has three enforcement lanes: class-level 5α-reductase inhibition (claims 1 and 10), structural formula I compounds (claims 2, 11 and narrowing 3-5, 12-14), and finasteride at 5 mg/day (claims 9 and 18).
- The dependent claims create clear, enforceable mappings to common clinical precipitating contexts: anesthesia/surgery, stroke/CHF, prostatitis/UTI, and medication triggers such as pseudoephedrine, cold medicines, narcotics, sedatives, and Benadryl.
- Design-around through chemistry alone is unlikely to avoid exposure because class-based method claims remain.
- Dose changes may avoid literal “5 mg/day” limitations for claims 9 and 18, but class-level claims can still apply if the administered regimen is still an effective 5α-reductase inhibition use for the claimed prophylaxis purpose.
FAQs
-
Does the patent claim finasteride only, or all 5α-reductase inhibitors?
It claims finasteride specifically at 5 mg/day (claims 9 and 18) and also claims methods using an inhibitor of 5α-reductase generally (claims 1 and 10).
-
Are precipitating triggers required in the broadest claims?
Not in claims 1 and 10. Trigger specificity is introduced in dependent claims (claims 6-8 and 15-17).
-
What makes claims 2 and 11 different from claims 1 and 10?
Claims 2 and 11 restrict the drug to structural formula I compounds with defined R substituent parameters.
-
Which triggers are explicitly enumerated and not just broadly described?
Stroke, congestive heart failure, prostatitis, urinary tract infection, and specific medications including pseudoephedrine hydrochloride, cold medicine, narcotics, sedatives, and Benadryl.
-
Can a product avoid the structural claims by using a different substituent pattern?
If the product does not match the structural formula I and R definitions, it can avoid those structural claims; however, it can still face class-based method exposure if it is still a 5α-reductase inhibitor used for the claimed prophylaxis.
References
[1] US Patent 5,942,519, “Method for reducing risk of precipitated acute urinary retention,” claims 1-18 (as provided in the prompt).
More… ↓
⤷ Start Trial
|
